Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 13, 2019

SELL
$77.91 - $109.6 $531,813 - $748,129
-6,826 Closed
0 $0
Q2 2019

Aug 16, 2019

SELL
$59.49 - $104.71 $20,107 - $35,391
-338 Reduced 4.72%
6,826 $703,000
Q1 2019

May 13, 2019

SELL
$43.65 - $78.95 $2,531 - $4,579
-58 Reduced 0.8%
7,164 $525,000
Q4 2018

Feb 13, 2019

BUY
$32.0 - $47.43 $5,536 - $8,205
173 Added 2.45%
7,222 $306,000
Q3 2018

Nov 13, 2018

BUY
$47.1 - $62.7 $92,739 - $123,456
1,969 Added 38.76%
7,049 $332,000
Q2 2018

Aug 10, 2018

BUY
$26.05 - $52.4 $132,334 - $266,192
5,080 New
5,080 $250,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track United Services Automobile Association Portfolio

Follow United Services Automobile Association and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of United Services Automobile Association, based on Form 13F filings with the SEC.

News

Stay updated on United Services Automobile Association with notifications on news.